Loading...
Loading...
ASND| Name | Value |
|---|---|
| Revenues | 137.7M |
| Cost of Revenue | 19.5M |
| Gross Profit | 118.2M |
| Operating Expense | 154.9M |
| Operating I/L | -36.6M |
| Other Income/Expense | 24.1M |
| Interest Income | -60.1M |
| Pretax | -81.1M |
| Income Tax Expense | 5.8M |
| Net Income/Loss | -86.9M |
Ascendis Pharma A/S is a biopharmaceutical company specializing in developing therapeutics for unmet medical needs. The company's flagship product, SKYTROFA, is designed to treat patients with growth hormone deficiency (GHD). Ascendis Pharma A/S also offers a range of other products, including TransCon Growth Hormone (hGH) for pediatric GHD, TransCon hGH for adults with GHD, TransCon parathyroid hormone for adult hypoparathyroidism, and TransCon CNP for pediatric achondroplasia. Additionally, the company is developing TransCon toll-like receptors 7/8 agonist for intratumoral delivery and TransCon IL-2 ß/g for systemic delivery.
